An assay system to detect the selective advantage of anti-HIV ribozyme expressing CD4+ T-lymphocytes.
This study was undertaken to establish an assay system to detect the survival advantage of anti-HIV ribozyme expressing cells under the selective pressure of HIV infection. In a mixture with wild type cells the proportion of ribozyme expressing cells was increased up to 12-fold. As a mechanism of the selective advantage an inhibition of HIV induced apoptotic cell death could be demonstrated. Furthermore, a dose dependency of the antiviral ribozyme effects was observed.
Klein
S A
SA
Medizinische Klinik III, Johann Wolfgang Goethe-Universität, Frankfurt, Germany.
Klebba
C
C
Engels
J W
JW
D000328:Adult; D017209:Apoptosis / Q000502:physiology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000201:enzymology* / Q000821:virology; D002478:Cells, Cultured; D005434:Flow Cytometry; D015316:Genetic Therapy; D005822:Genetic Vectors; D015658:HIV Infections / Q000628:therapy; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D016337:RNA, Catalytic / Q000096:biosynthesis / Q000235:genetics*; D020800:Receptor, Nerve Growth Factor / Q000096:biosynthesis / Q000235:genetics; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic
D016337:RNA, Catalytic; D020800:Receptor, Nerve Growth Factor; C418481:hairpin ribozyme